Literature DB >> 2734275

The fecal chymotrypsin photometric assay in the evaluation of exocrine pancreatic capacity. Comparison with other direct and indirect pancreatic function tests.

G Cavallini1, L Benini, G Brocco, A Riela, P Bovo, P Pederzoli, G Angelini, C Pelle, G Bertelli, L A Scuro.   

Abstract

Fecal chymotrypsin (FCT) has been measured by a new photometric method (Monotest Chymotrypsin; Boehringer, Mannheim) in 78 patients: 44 with chronic pancreatitis and 34 not affected by any pancreatic disease. The results were compared with those from other tests of pancreatic secretory (secretin-cerulein test) and digestive [serum and urinary p-aminobenzoic acid (PABA) and pancreolauryl] capacity. When FCT values were severely reduced (below 6.7 U/g), from 90 to 100% of the patients also presented abnormal pancreatic secretory and digestive capacity. On the other hand, 87% of the patients with normal FCT (above 20 U/g) presented normal secretory and digestive capacity. Patients with intermediate FCT values (between 6.7 and 20 U/g) showed normal or abnormal pancreatic secretory and digestive capacity with the same probability. Therefore, FCT, carried out as a first test, seems to identify subjects that need no further pancreatic function tests (normal and severely impaired FCT) and patients who need other more complex functional investigations (intermediate FCT values).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2734275     DOI: 10.1097/00006676-198906000-00005

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  5 in total

Review 1.  Pancreatic function tests: when to choose, what to use.

Authors:  W G Boeck; G Adler; T M Gress
Journal:  Curr Gastroenterol Rep       Date:  2001-04

2.  Guidelines for the investigation of chronic diarrhoea, 2nd edition.

Authors:  P D Thomas; A Forbes; J Green; P Howdle; R Long; R Playford; M Sheridan; R Stevens; R Valori; J Walters; G M Addison; P Hill; G Brydon
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

3.  Limitations of faecal chymotrypsin as a screening test.

Authors:  G Cavallini; L Benini
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

4.  Surgery for chronic pancreatitis: what quality of life ahead?

Authors:  P Petrin; A Andreoli; M Antoniutti; D Zaramella; C Da Lio; B Bonadimani; L Garbin; S Pedrazzoli
Journal:  World J Surg       Date:  1995 May-Jun       Impact factor: 3.352

5.  Alterations of exocrine pancreas in end-stage renal disease. Do they reflect a clinically relevant uremic pancreopathy?

Authors:  M Ventrucci; C Campieri; M Di Stefano; G M Ubalducci; S Li Bassi; A Di Grazia; A Giudicissi; D Festi
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.